Trial Profile

A phase I/II study of LAE102 targeting solid tumors, with the indication of Non-Small Cell Lung Cancer (NSCLC)

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LAE 102 (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions
Sponsors Laekna Therapeutics

Most Recent Events

25 May 2023 New trial record
21 May 2023 According to Laekna Therapeutics media release, the company has received the first IND clearance by U.S. FDA for this phase I/II trial. this is company's first internally-discovered drug candidate to obtain IND clearance, reflecting the company's strength in internal discovery.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com